Histone deacetylase as a therapeutic target
- 1 September 2001
- journal article
- review article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 12 (7) , 294-300
- https://doi.org/10.1016/s1043-2760(01)00438-6
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- The Human Histone Deacetylase FamilyExperimental Cell Research, 2001
- Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid CellsJapanese Journal of Cancer Research, 2000
- The language of covalent histone modificationsNature, 2000
- IGF-II Enhances Trichostatin A-Induced TGFβ1 and p21Waf1,Cip1,Sdi1 Expression in Hep3B CellsExperimental Cell Research, 1999
- Effects of Cell Density and Trichostatin A on the Expression ofHDAC1andp57Kip2in Hep 3B CellsBiochemical and Biophysical Research Communications, 1998
- Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APLNature Genetics, 1998
- What's Up and Down with Histone Deacetylation and Transcription?Cell, 1997
- Thyroid Hormone Resistance Syndrome Manifests as an Aberrant Interaction between Mutant T3 Receptors and Transcriptional CorepressorsMolecular Endocrinology, 1997
- Butyrate inhibits seeding and growth of colorectal metastases to the liver in miceSurgery, 1996
- Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat modelGastroenterology, 1996